Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlobeImmune (GBIM)
OTHER OTC:GBIM
Holding GBIM?
Track your performance easily
GBIM Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
Volume100.00
Average Volume (3M)103.00
Market Cap
$6.00
Enterprise ValueN/A
Total Cash (Recent Filing)$15.15M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,752,000
10 Day Avg. Volume300
30 Day Avg. Volume103
Standard Deviation69.87
R-Squared0.03
Alpha11.69
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.32
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
11.43% Other Institutional Investors
88.57% Public Companies and
Individual Investors
GBIM FAQ
What was GlobeImmune’s price range in the past 12 months?
Currently, no data Available
What is GlobeImmune’s market cap?
GlobeImmune’s market cap is $6.00.
When is GlobeImmune’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were GlobeImmune’s earnings last quarter?
Currently, no data Available
Is GlobeImmune overvalued?
According to Wall Street analysts GlobeImmune’s price is currently Overvalued.
Does GlobeImmune pay dividends?
GlobeImmune does not currently pay dividends.
What is GlobeImmune’s EPS estimate?
GlobeImmune’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlobeImmune have?
GlobeImmune has 5,752,000 shares outstanding.
What happened to GlobeImmune’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of GlobeImmune?
Currently, no hedge funds are holding shares in GBIM
---
Company Description
GlobeImmune
GlobeImmune, Inc. is a biopharmaceutical company. It engages in the development of therapeutic products for cancer and infectious diseases based on its proprietary Tarmogen platform. The company was founded by Donald Bellgrau, Richard C. Duke, and Alex Franzusoff on February 10, 1995 and is headquartered in Louisville, CO.
---
---